Nanotechnological interventions in dermatophytosis: from oral to topical, a fresh perspective

References

• Nigam PK. Antifungal drugs and resistance: current concepts. Our Dermatol Online. 2015;6(2):212.
   Google Scholar
• Achterman RR, Smith AR, Oliver BG, et al. Sequenced dermatophyte strains: growth rate, conidiation, drug susceptibilities, and virulence in an invertebrate model. Fungal Genet Biol. 2011;48(3):335–341.
   PubMed Web of Science ®Google Scholar
• White TC, Findley K, Dawson TL, et al. Fungi on the skin: dermatophytes and Malassezia. Cold Spring Harb Perspect Med. 2014;4(8):a019802.
   PubMed Web of Science ®Google Scholar
• Baltazar LM, Ray A, Santos DA, et al. Antimicrobial photodynamic therapy: an effective alternative approach to control fungal infections. Front Microbiol. 2015;6:202.
   PubMed Web of Science ®Google Scholar
• Rajagopalan M, Inamadar A, Mittal A, et al. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6.
   PubMed Web of Science ®Google Scholar
• White TC, Oliver BG, Gräser Y, et al. Generating and testing molecular hypotheses in the dermatophytes. Eukaryot Cell. 2008;7(8):1238–1245.
   PubMedGoogle Scholar
• Zhan P, Liu W. The changing face of dermatophytic infections worldwide. Mycopathologia. 2017;182(1–2):77–86.
   PubMed Web of Science ®Google Scholar
• Philpot CM. Geographical distribution of the dermatophytes: a review. J Hyg (Lond). 1978;80(2):301–313.
   PubMedGoogle Scholar
• Mirmirani P, Tucker LY. Epidemiologic trends in pediatric tinea capitis: a population-based study from Kaiser Permanente Northern California. J Am Acad Dermatol. 2013;69(6):916–921.
   PubMed Web of Science ®Google Scholar
• Borman AM, Campbell CK, Fraser M, et al. Analysis of the dermatophyte species isolated in the British Isles between 1980 and 2005 and review of worldwide dermatophyte trends over the last three decades. Med Mycol. 2007;45(2):131–141.
   PubMed Web of Science ®Google Scholar
• Zhan P, Geng C, Li Z, et al. Evolution of tinea capitis in the Nanchang area, Southern China: a 50-year survey (1965–2014). Mycoses. 2015;58(5):261–266.
   PubMed Web of Science ®Google Scholar
• Zhan P, Li D, Wang C, et al. Epidemiological changes in tinea capitis over the sixty years of economic growth in China. Med Mycol. 2015;53(7):691–698.
   PubMed Web of Science ®Google Scholar
• Mapelli ET, Cerri A, Bombonato C, et al. Tinea capitis in the paediatric population in Milan, Italy: the emergence of Trichophyton violaceum. Mycopathologia. 2013;176(3–4):243–246.
   PubMed Web of Science ®Google Scholar
• Zhu M, Li L, Wang J, et al. Tinea capitis in Southeastern China: a 16-year survey. Mycopathologia. 2010;169(4):235–239.
   PubMed Web of Science ®Google Scholar
• Duran-Valle MT, Regodon-Dominguez M, Velasco-Rodriguez MJ, et al. Outbreak of Trichophyton tonsurans ringworm in a health area of the community of Madrid (Spain). Rev Iberoam Micol. 2016;33(2):126–128.
   PubMed Web of Science ®Google Scholar
• Degreef HJ, DeDoncker PR. Current therapy of dermatophytosis. J Am Acad Dermatol. 1994;31(3):S25–S30.
   PubMed Web of Science ®Google Scholar
• Tainwala R, Sharma Y. Pathogenesis of dermatophytoses. Indian J Dermatol. 2011;56(3):259.
   PubMedGoogle Scholar
• Vermout S, Tabart J, Baldo A, et al. Pathogenesis of dermatophytosis. Mycopathologia. 2008;166(5–6):267–275.
   PubMed Web of Science ®Google Scholar
• Aljabre SH, Richardson MD, Scott EM, et al. Adherence of arthroconidia and germlings of anthropophilic and zoophilic varieties of Trichophyton mentagrophytes to human corneocytes as an early event in the pathogenesis of dermatophytosis. Clin Exp Dermatol. 1993;18(3):231–235.
   PubMed Web of Science ®Google Scholar
• Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol. 1993;28(5):S2–S7.
   PubMed Web of Science ®Google Scholar
• Dogra SNT. Emerging atypical and unusual presentations of dermatophytosis in India. Clin Dermatol Rev. 2017;1(3):12–18.
   Google Scholar
• Naglot ASD, Nath BK, Gogoi HK, et al. Recent trends of dermatophytosis in Northeast India (Assam) and interpretation with published studies. Int J Curr Microbiol Appl Sci. 2015;4(11):111–120.
   Google Scholar
• Verma S, Madhu R. The Great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62(3):227–236.
   PubMed Web of Science ®Google Scholar
• Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: is the problem deeper than we perceive? Indian Dermatol Online J. 2016;7(2):73–76.
   PubMedGoogle Scholar
• Sahni K, Singh S, Dogra S. Newer topical treatments in skin and nail dermatophyte infections. Indian Dermatol Online J. 2018;9(3):149.
   PubMedGoogle Scholar
• Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA dermatol. 2013;149(3):341–349.
   PubMed Web of Science ®Google Scholar
• Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol. 1989;14(2):124–127.
   PubMed Web of Science ®Google Scholar
• Millikan LE, Galen WK, Gewirtzman GB, et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol. 1988;18(1):52–56.
   PubMed Web of Science ®Google Scholar
• Van Zuuren E, Fedorowicz Z, El‐Gohary M. Evidence‐based topical treatments for tinea cruris and tinea corporis: a summary of a cochrane systematic review. Br J Dermatol. 2015;172(3):616–641.
   PubMed Web of Science ®Google Scholar
• Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2–7.
   PubMed Web of Science ®Google Scholar
• El-Gohary M, van Zuuren EJ, Fedorowicz Z, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014;8:Cd009992.
   Google Scholar
• Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014;5(2):128–131.
   PubMedGoogle Scholar
• Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008;12(2):51–58.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Parish LC, Vlahovic T, et al. Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol. 2013;12(8):911–918.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Vlahovic T, Verma A, et al. Naftifine hydrochloride gel 2%: an effective topical treatment for moccasin-type tinea pedis. J Drugs Dermatol. 2015;14(10):1138–1144.
   PubMed Web of Science ®Google Scholar
• Vlahovic TC. The role of naftifine HCl 2% gel and cream in treating moccasin tinea pedis. J Drugs Dermatol. 2016;15(2 Suppl):s56–s9.
   PubMed Web of Science ®Google Scholar
• Singal A. Butenafine and superficial mycoses: current status. Expert Opin Drug Metab Toxicol. 2008;4(7):999–1005.
   PubMed Web of Science ®Google Scholar
• Thaker SJ, Mehta DS, Shah HA, et al. A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2% sertaconazole and topical 1% butenafine in tinea infections of skin. Indian J Dermatol. 2013;58(6):451–456.
   PubMedGoogle Scholar
• Thaker SJ, Mehta DS, Shah HA, et al. A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield’s ointment + oral fluconazole versus topical 1% butenafine in tinea infections of skin. Indian J Pharmacol. 2013;45(6):622–624.
   PubMed Web of Science ®Google Scholar
• Saunders J, Maki K, Koski R, et al. Tavaborole, efinaconazole, and luliconazole: three new antimycotic agents for the treatment of dermatophytic fungi. J Pharm Pract. 2017;30(6):621–630.
   PubMedGoogle Scholar
• Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182(1–2):127–141.
   PubMed Web of Science ®Google Scholar
• Banerjee M, Ghosh AK, Basak S, et al. Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. Indian J Dermatol. 2011;56(6):657.
   PubMedGoogle Scholar
• Polak AM. Preclinical data and mode of action of amorolfine. Dermatol. 1992;17(s1):8–12.
   Google Scholar
• Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatol. 1992;184(Suppl. 1):21–24.
   PubMed Web of Science ®Google Scholar
• Del Palacio A, López-Gómez S, García-Bravo M, et al. Experience with amorolfine in the treatment of dermatomycoses. Dermatol. 1992;18(Suppl. 1):25–29.
   Web of Science ®Google Scholar
• Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7(2):77.
   PubMedGoogle Scholar
• Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum: study after oral administration in man. Arch Dermatol. 1972;106(3):344–348.
   PubMedGoogle Scholar
• Reynolds JEF. Martindale: the extra pharmacopoeia. 28th ed. London (UK): The Pharmaceutical Press; 1982.
   Google Scholar
• Faergemann J, Mörk N, Haglund A, et al. A multicentre (double‐blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol. 1997;136(4):575–577.
   PubMed Web of Science ®Google Scholar
• Cole G, Stricklin G. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol. 1989;125(11):1537–1539.
   PubMedGoogle Scholar
• Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women. Indian Dermatol Online J. 2017;8(5):310.
   PubMedGoogle Scholar
• Bourlond A, Lachapelle J-M, Aussems J, et al. Double‐blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol. 1989;28(6):410–412.
   PubMed Web of Science ®Google Scholar
• Artis W. Final pathway for delivery of oral antifungals to keratinized cornified skin, in oral therapy in dermatomycoses: a step forward. Med Educ Serv Oxford. 1985;61–70.
   Google Scholar
• Harris R, Jones H, Artis W. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother. 1983;24(6):876–882.
   PubMed Web of Science ®Google Scholar
• Cauwenbergh G. Skin mycoses: effects of ketoconazole and itraconazole in relation to drug distribution in the skin[Thesis]. Belgium: Catholic University Leuven; 1988.
   Google Scholar
• Borelli D. Treatment of pityriasis versicolor with ketoconazole. Rev Infect Dis. 1980;2(4):592–595.
   PubMedGoogle Scholar
• Rausch L, Jacobs PJC. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis. 1984;34(5):470–471.
   PubMed Web of Science ®Google Scholar
• Segal R, Trattner A, Alteras I, et al. Once-weekly treatment with oral ketoconazole for superficial fungal infections. J Am Acad Dermatol. 1993;28(1):26–27.
   Web of Science ®Google Scholar
• Jones H. Ketoconazole today: a review of clinical experience. Germany: ADIS Press; 1987. p. 99.
   Google Scholar
• Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol. 1990;23(4):782–785.
   PubMed Web of Science ®Google Scholar
• Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol. 1990;23(3):554–558.
   PubMed Web of Science ®Google Scholar
• Nuijten S, Schuller J. Itraconazole in the treatment of tinea corporis: a pilot study. Rev Infect Dis. 1987;9(Supplement_1):S119–S120.
   PubMedGoogle Scholar
• Cauwenbergh G, De Doncker P. The clinical use of itraconazole in superficial and deep mycoses, in recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers; 1987. p. 273–284.
   Google Scholar
• Degreef H, Mariën K, De Veylder H, et al. Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. Rev Infect Dis. 1987;9(Supplement_1):S104–S108.
   PubMedGoogle Scholar
• Brammer K, Farrow P, Faulkner J. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Supplement_3):S318–S326.
   PubMedGoogle Scholar
• Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatol. 1998;196(2):237–241.
   PubMed Web of Science ®Google Scholar
• De Cuyper C. Noncomparative study of fluconazole in the treatment of patients with common fungal infections of the skin. Int J Dermatol. 1992;31(2):17–20.
   Web of Science ®Google Scholar
• Naeyaert J, de Bersaques J, de Cuyper C, et al. Fluconazole (UK-49,858): A novel oral antifungal, in the tratment of fungal skin infections. Results of an open study in 43 patients. In: Ra F, Jr P, editors. Recent trends in the discovery, development and evaluation of antifungal agents. USA: JR Prous Science Publishers, SA, USA. Science Publications; 1987. p. 157–161.
   Google Scholar
• Andrews MD, Burns M. Common tinea infections in children. AM FAM Physician. 2008;77(10):1415–1420.
   PubMed Web of Science ®Google Scholar
• Ely J, Rosenfeld S, Seabury S. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90(10):702–710.
   PubMed Web of Science ®Google Scholar
• Hainer BL. Dermatophyte infections. AM FAM Physician. 2003;67(1):101–110.
   PubMed Web of Science ®Google Scholar
• Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. Front Med. 2016;3:11.
   PubMed Web of Science ®Google Scholar
• Rai M, Ingle A, Pandit R, et al. The microbiology of skin, soft tissue, bone and joint infections. In: Kon K, Rai M, editors, Nanotechnology for the treatment of fungal infections on human skin. Amsterdam: Elsevier; 2017. p. 169–184.
   Google Scholar
• Peres N, Maranhão FCA, Rossi A, et al. Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol. 2010;85(5):657–667.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Chaturvedi V, Espinel-Ingroff A, et al. Intra-and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol. 2004;42(7):2977–2979.
   PubMed Web of Science ®Google Scholar
• Singh S, Shukla P. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol. 2018;84(5):554–557.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee R, Dogra S. End of the road for terbinafine’ in dermatophytosis: is it a valid conclusion? Indian J Dermatol Venereol Leprol. 2018;84(6):706–707.
   PubMed Web of Science ®Google Scholar
• Verma SB, Vasani R. Male genital dermatophytosis - clinical features and the effects of the misuse of topical steroids and steroid combinations - an alarming problem in India. Mycoses. 2016;59(10):606–614.
   PubMed Web of Science ®Google Scholar
• Pathania S, Rudramurthy SM, Narang T, et al. A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. Indian J Dermatol Venereol Leprol. 2018;84(6):678–684.
   PubMed Web of Science ®Google Scholar
• Yamada T, Maeda M, Alshahni MM, et al. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61(7):e00115–e00117.
   PubMed Web of Science ®Google Scholar
• Singh A, Masih A, Khurana A, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61(7):477–484.
   PubMed Web of Science ®Google Scholar
• Rudramurthy SM, Shankarnarayan SA, Dogra S, et al. Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance. Antimicrob Agents Chemother. 2018;62(5):e02522–e17.
   PubMed Web of Science ®Google Scholar
• Nowosielski M, Hoffmann M, Wyrwicz LS, et al. Detailed mechanism of squalene epoxidase inhibition by terbinafine. J Chem Inf Model. 2011;51(2):455–462.
   PubMed Web of Science ®Google Scholar
• Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012:1–26.
   Google Scholar
• Lewis D, Rodrigues A, Ioannides C, et al. Adverse reactions of imidazole antifungal agents: computer graphic studies of cytochrome P‐450 interactions. J Biochem Mol Toxicol. 1989;4(4):231–234.
   Web of Science ®Google Scholar
• Rosenberger A, Tebbe B, Treudler R, et al. Acute generalized exanthematous pustulosis induced by nystatin. Dermatol. 1998;49(6):492–495.
   Google Scholar
• Myers R. Antifungal agents, in immunizing and antimicrobial agents. Germany: Springer; 2006. p. 01–6.
   Google Scholar
• Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008;166(5–6):369.
   PubMed Web of Science ®Google Scholar
• Villars V, Jones T. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatolog Treat. 1990;1(sup2):33–38.
   Google Scholar
• Haneke E. Pharmacokinetic evaluation of fluconazole in plasma, epidermis, and blister fluid. Int J Dermatol. 1992;31:3.
   Google Scholar
• Fischbein A. Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. Int J Dermatol. 1992;31(2):12–16.
   Google Scholar
• Alcantra R, Caribay JM. Itraconazole therapy in dermatomycosis and vaginal candidiasis: efficacy and adverse effects profile in a large multicenter study. Adv Ther. 1988;5:326–334.
   Google Scholar
• Greer D. Clinical consequences of new pharmacological concepts in cutaneous fungal infections. J Eur Acad Dermatol Venereol. 1993;2:S26–S33.
   Google Scholar
• Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–1316.
   PubMed Web of Science ®Google Scholar
• Soliman GM. Nanoparticles as safe and effective delivery systems of antifungal agents: achievements and challenges. Int J Pharm. 2017;523(1):15–32.
   PubMed Web of Science ®Google Scholar
• Tuncay Tanrıverdi S, Hilmioğlu Polat S, Yeşim Metin D, et al. Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation. J Liposome Res. 2016;26(2):163–173.
   PubMed Web of Science ®Google Scholar
• Erdal MS, Özhan G, Mat MC, et al. Colloidal nanocarriers for the enhanced cutaneous delivery of naftifine: characterization studies and in vitro and in vivo evaluations. Int J Nanomed. 2016;11:1027.
   PubMed Web of Science ®Google Scholar
• Beg S, Sharma G, Samad A. Liposomes for drug delivery across the blood–brain barrier. In: Bough A, editor, Liposomal delivery systems: advances and challenges. London: Future Science Group; 2016. p. 132–142.
   Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–2):1–20.
   PubMed Web of Science ®Google Scholar
• Knight CG. Liposomes, from physical structure to therapeutic applications, ed. Knight CG. New York: Elsevier/North-Holland Biomedical Press; 1981. p. 497.
   Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975.
   PubMed Web of Science ®Google Scholar
• Forssen EA, Tökès Z. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci. 1981;78(3):1873–1877.
   PubMed Web of Science ®Google Scholar
• Forssen EA, Tökes ZA. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 1983;43(2):546–550.
   PubMed Web of Science ®Google Scholar
• Eloy JO, de Souza MC, Petrilli R, et al. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 2014;123:345–363.
   PubMed Web of Science ®Google Scholar
• Fathalla D, Soliman G, Fouad E. Development and in vitro/in vivo evaluation of liposomal gels for the sustained ocular delivery of latanoprost. Clin Exp Ophthalmol. 2015;6(2):1–9.
   Google Scholar
• McClements DJ. Encapsulation, protection, and release of hydrophilic active components: potential and limitations of colloidal delivery systems. Adv Colloid Interface Sci. 2015;219:27–53.
   PubMed Web of Science ®Google Scholar
• Deniz A, Sade A, Severcan F, et al. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Biosci Rep. 2010;30(5):365–373.
   PubMed Web of Science ®Google Scholar
• Foldvari M, Gesztes A, Mezei M. Dermal drug delivery by liposome encapsulation: clinical and electron microscopic studies. J Microencapsul. 1990;7(4):479–489.
   PubMed Web of Science ®Google Scholar
• Elzainy AA, Gu X, Simons FER, et al. Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. AAPS PharmSci. 2003;5(4):41–48.
   Google Scholar
• Akhtar N. Vesicles: a recently developed novel carrier for enhanced topical drug delivery. Curr Drug Deliv. 2014;11(1):87–97.
   PubMed Web of Science ®Google Scholar
• Kumar L, Verma S, Bhardwaj A, et al. Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review. Artif Cells Nanomed Biotechnol. 2014;42(1):32–46.
   PubMed Web of Science ®Google Scholar
• Maghraby GME, Williams AC, Barry BW. Skin hydration and possible shunt route penetration in controlled estradiol delivery from ultradeformable and standard liposomes. J Pharm Pharmacol. 2001;53(10):1311–1322.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu Q, Zhang Z, et al. Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules. 2012;17(5):5972–5987.
   PubMed Web of Science ®Google Scholar
• Sudhakar B, Ravi VJ, Ramana MK. Formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery. Curr Drug Deliv. 2014;11(4):521–530.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Katare O. Miconazole nitrate–loaded topical liposomes. Pharm Technol. 2002;26:48–60.
   Google Scholar
• Verma A, Palani S. Development and in-vitro evaluation of liposomal gel of ciclopirox olamine. Int J Pharm Biol Sci. 2010;1(2):1–6.
   Google Scholar
• Patel RP, Patel H, Baria AH. Formulation and evaluation of liposomes of ketoconazole. Int J Drug Delivery Technol. 2009;1(1):16–23.
   Google Scholar
• Mitkari B, Korde S, Mahadik K, et al. Formulation and evaluation of topical liposomal gel for fluconazole. Indian J Pharm Educ Res. 2010;44(4):324–333.
   Web of Science ®Google Scholar
• Hänel H, Braun B, Jovic N. Comparative activity of a liposomal and a conventional econazole preparation for topical use according to a guinea pig tinea model. In: Falco B, Otto, Korting, Hans C, Maibach, Howard I, editors, Liposome dermatics. Germany: Springer; 1992. p. 251–257.
   Google Scholar
• Romero EL, Morilla MJ. Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. Int J Nanomedicine. 2013;8:3171.
   PubMed Web of Science ®Google Scholar
• Morrow D, McCarron P, Woolfson A, et al. Innovative strategies for enhancing topical and transdermal drug delivery. Open Drug Delivery J. 2007;1:36–59.
   Google Scholar
• Shilakari G, Singh D, Asthana A. Novel vesicular carriers for topical drug delivery and their applications. Int J Pharm Sci Rev Res. 2013;21(1):77–86.
   Google Scholar
• Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta. 1992;1104(1):226–232.
   PubMed Web of Science ®Google Scholar
• Kumar A, Pathak K, Bali V. Ultra-adaptable nanovesicular systems: a carrier for systemic delivery of therapeutic agents. Drug Discov Today. 2012;17(21–22):1233–1241.
   PubMed Web of Science ®Google Scholar
• Elsayed MM, Abdallah OY, Naggar VF, et al. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322(1–2):60–66.
   PubMed Web of Science ®Google Scholar
• Cevc G. Transfersomes: innovative transdermal drug carriers. In: Rathbone M, Hadgraft J, editors. Modified-release drug delivery technology. London: Taylor & Francis Group; 2003. p. 533–546.
   Google Scholar
• Aggarwal N, Goindi S. Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis—dermatophytosis. Int J Pharm. 2012;437(1–2):277–287.
   PubMed Web of Science ®Google Scholar
• Alomrani AH, Shazly GA, Amara AA, et al. Itraconazole-hydroxypropyl-β-cyclodextrin loaded deformable liposomes: in vitro skin penetration studies and antifungal efficacy using Candida albicans as model. Colloids Surf B Biointerfaces. 2014;121:74–81.
   PubMed Web of Science ®Google Scholar
• Pandit J, Garg M, Jain NK. Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection. J Liposome Res. 2014;24(2):163–169.
   PubMed Web of Science ®Google Scholar
• Zhang YT, Shen LN, Zhao JH, et al. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int J Nanomedicine. 2014;9(1):669.
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Bergelson L, et al. Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65(3):403–418.
   PubMed Web of Science ®Google Scholar
• Verma P, Pathak K. Therapeutic and cosmeceutical potential of ethosomes: an overview. J Adv Pharm Technol Res. 2010;1(3):274.
   PubMedGoogle Scholar
• Ainbinder D, Paolino D, Fresta M, et al. Drug delivery applications with ethosomes. J Biomed Nanotechnol. 2010;6(5):558–568.
   PubMed Web of Science ®Google Scholar
• Nanda A, Nanda S, Khan GN. Current developments using emerging transdermal technologies in physical enhancement methods. Curr Drug Deliv. 2006;3(3):233–242.
   PubMedGoogle Scholar
• Zhang Z, Wo Y, Zhang Y, et al. In vitro study of ethosome penetration in human skin and hypertrophic scar tissue. Nanomedicine. 2012;8(6):1026–1033.
   PubMed Web of Science ®Google Scholar
• Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62(4–5):478–490.
   PubMed Web of Science ®Google Scholar
• Chen J-G, Liu Y-F, Gao T-W. Preparation and anti-inflammatory activity of triptolide ethosomes in an erythema model. J Liposome Res. 2010;20(4):297–303.
   PubMed Web of Science ®Google Scholar
• Saraf S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010;81(7):680–689.
   PubMed Web of Science ®Google Scholar
• Blume A, Jansen M, Ghyczy M, et al. Interaction of phospholipid liposomes with lipid model mixtures for stratum corneum lipids. Int J Pharm. 1993;99(2–3):219–228.
   Web of Science ®Google Scholar
• Campani V, Biondi M, Mayol L, et al. Nanocarriers to enhance the accumulation of vitamin K1 into the skin. Pharm Res. 2016;33(4):893–898.
   PubMed Web of Science ®Google Scholar
• Faisal W, Soliman GM, Hamdan AM. Enhanced skin deposition and delivery of voriconazole using ethosomal preparations. J Liposome Res. 2018;28(1):14–21.
   PubMed Web of Science ®Google Scholar
• Maheshwari RG, Tekade RK, Sharma PA, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J. 2012;20(2):161–170.
   PubMed Web of Science ®Google Scholar
• Bhalaria M, Naik S, Misra A. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol. 2009;47(5):368–375.
   PubMed Web of Science ®Google Scholar
• Lachenmeier DW. Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity. J Occup Med Toxicol. 2008;3(1):26.
   PubMed Web of Science ®Google Scholar
• Akhtar N, Pathak K. Cavamax w7 composite ethosomal gel of clotrimazole for improved topical delivery: development and comparison with ethosomal gel. AAPS PharmSciTech. 2012;13(1):344–355.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1–2):33–70.
   Web of Science ®Google Scholar
• Date A, Naik B, Nagarsenker M. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol. 2006;19(1):2–16.
   Google Scholar
• Thakkar M. Opportunities and challenges for niosomes as drug delivery systems. Curr Drug Deliv. 2016;13(8):1275–1289.
   PubMed Web of Science ®Google Scholar
• Florence A. Nonionic surfactant vesicles: preparation and characterization. Int J Pharmtech Res. 1993;2:157–176.
   Google Scholar
• Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22–36.
   PubMed Web of Science ®Google Scholar
• Azmin M, Florence A, Handjani‐Vila R, et al. The effect of non‐ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol. 1985;37(4):237–242.
   PubMed Web of Science ®Google Scholar
• Baillie A, Florence A, Hume L, et al. The preparation and properties of niosomes—non‐ionic surfactant vesicles. J Pharm Pharmacol. 1985;37(12):863–868.
   PubMed Web of Science ®Google Scholar
• Handjani‐Vila R, Ribier A, Rondot B, et al. Dispersions of lamellar phases of non‐ionic lipids in cosmetic products. Int J Cosmet Sci. 1979;1(5):303–314.
   PubMed Web of Science ®Google Scholar
• Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target. 2009;17(9):671–689.
   PubMed Web of Science ®Google Scholar
• Reddy DN, Udupa N. Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev Ind Pharm. 1993;19(7):843–852.
   Web of Science ®Google Scholar
• Niemiec S, Hu Z, Ramachandran C, et al. The effect of dosing volume on the disposition of cyclosporin A in hairless mouse skin after topical application of a non-ionic liposomal formulation: an in vitro diffusion study. STP Pharm Sci. 1994;4(2):145–149.
   Google Scholar
• Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release. 1994;30(1):1–15.
   Web of Science ®Google Scholar
• Van Hal D, Van Rensen A, De Vringer T, et al. Diffusion of estradiol from non-ionic surfactant vesicles through human stratum corneum in vitro. STP Pharm Sci. 1996;6(1):72–78.
   Google Scholar
• Junginger H, Hofland H, Bouwstra J. Liposomes and niosomes: interactions with human skin. Cosmet Toiletries. 1991;106(8):45–50.
   Google Scholar
• Kassem MA, Esmat S, Bendas ER, et al. Efficacy of topical griseofulvin in treatment of tinea corporis. Mycoses. 2006;49(3):232–235.
   PubMed Web of Science ®Google Scholar
• Shirsand S, Para M, Nagendrakumar D, et al. Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. Int J Pharm Investig. 2012;2(4):201.
   PubMedGoogle Scholar
• Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438–470.
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131–S155.
   PubMed Web of Science ®Google Scholar
• Müller R, Dingler A. The next generation after the liposomes: solid lipid nanoparticles (SLN, Lipopearls) as dermal carrier in cosmetics. Eurocosmetics. 1998;7(8):19–26.
   Google Scholar
• Muller R, Dingler A. Feste lipid-nanopartikel als neuartige carrier fur wirkstoffe. Pharm Ztg. 1998;143(49):11–15.
   Google Scholar
• Liu J, Hu W, Chen H, et al. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328(2):191–195.
   PubMed Web of Science ®Google Scholar
• Müller RH, Maèder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
   PubMed Web of Science ®Google Scholar
• Wissing S, Müller R. Solid lipid nanoparticles (SLN)–a novel carrier for UV blockers. Pharmazie. 2001;56(10):783–786.
   PubMed Web of Science ®Google Scholar
• Lv Q, Yu A, Xi Y, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372(1–2):191–198.
   PubMed Web of Science ®Google Scholar
• Vaghasiya H, Kumar A, Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci. 2013;49(2):311–322.
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Liu D-Z, Liu -J-J, et al. Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomed. 2012;7:4409.
   PubMed Web of Science ®Google Scholar
• Bhalekar MR, Pokharkar V, Madgulkar A, et al. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009;10(1):289–296.
   PubMed Web of Science ®Google Scholar
• Aggarwal N, Goindi S. Preparation and in vivo evaluation of solid lipid nanoparticles of griseofulvin for dermal use. J Biomed Nanotechnol. 2013;9(4):564–576.
   PubMed Web of Science ®Google Scholar
• El-Housiny S, Shams Eldeen MA, El-Attar YA, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study. Drug Deliv. 2018;25(1):78–90.
   PubMed Web of Science ®Google Scholar
• Gupta M, Tiwari S, Vyas SP. Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm Dev Technol. 2013;18(3):550–559.
   PubMed Web of Science ®Google Scholar
• Souto E, Müller R. SLN and NLC for topical delivery of ketoconazole. J Microencapsul. 2005;22(5):501–510.
   PubMed Web of Science ®Google Scholar
• Souto E, Wissing S, Barbosa C, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278(1):71–77.
   PubMed Web of Science ®Google Scholar
• Garg NK, Singh B, Tyagi RK, et al. Effective transdermal delivery of methotrexate through nanostructured lipid carriers in an experimentally induced arthritis model. Colloids Surf B Biointerfaces. 2016;147:17–24.
   PubMed Web of Science ®Google Scholar
• Garg NK, Tyagi RK, Singh B, et al. Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-kappaB and FOXO1. Int J Pharm. 2016;499(1–2):301–320.
   PubMed Web of Science ®Google Scholar
• Garg NK, Sharma G, Singh B, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): an improved dermatokinetic profile for inflammatory disorder (s). Int J Pharm. 2017;517(1–2):413–431.
   PubMed Web of Science ®Google Scholar
• Nirbhavane P, Sharma G, Singh B, et al. Preclinical explorative assessment of celecoxib-based biocompatible lipidic nanocarriers for the management of CFA-induced rheumatoid arthritis in wistar rats. AAPS PharmSciTech. 2018;19(7):3187–3198.
   PubMed Web of Science ®Google Scholar
• Sharma G, Thakur K, Raza K, et al. Nanostructured lipid carriers: a new paradigm in topical delivery for dermal and transdermal applications. Crit Rev Ther Drug Carrier Syst. 2017;34(4):355–386.
   PubMed Web of Science ®Google Scholar
• Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7–22.
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Md S, Sahni JK, et al. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813–830.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh M, Tripathi CB, et al. Development and evaluation of ultra-small nanostructured lipid carriers: novel topical delivery system for athlete’s foot. Drug Deliv Transl Res. 2016;6(1):38–47.
   PubMed Web of Science ®Google Scholar
• Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids. 2012;165(4):454–461.
   PubMed Web of Science ®Google Scholar
• Iqbal B, Ali J, Baboota S. Recent advances and development in epidermal and dermal drug deposition enhancement technology. Int J Dermatol. 2018;57(6):646–660.
   PubMed Web of Science ®Google Scholar
• Vimbela GV, Ngo SM, Fraze C, et al. Antibacterial properties and toxicity from metallic nanomaterials. Int J Nanomedicine. 2017;12:3941–3965.
   PubMed Web of Science ®Google Scholar
• Rao CN, Kulkarni GU, Thomas PJ, et al. Size-dependent chemistry: properties of nanocrystals. Chemistry. 2002;8(1):28–35.
   PubMed Web of Science ®Google Scholar
• Ivask A, Elbadawy A, Kaweeteerawat C, et al. Toxicity mechanisms in Escherichia coli vary for silver nanoparticles and differ from ionic silver. ACS Nano. 2014;8(1):374–386.
   PubMed Web of Science ®Google Scholar
• Hebbalalu D, Lalley J, Nadagouda MN, et al. Greener techniques for the synthesis of silver nanoparticles using plant extracts, enzymes, bacteria, biodegradable polymers, and microwaves. ACS Sustain Chem Eng. 2013;1(7):703–712.
   Web of Science ®Google Scholar
• Ronavari A, Igaz N, Gopisetty MK, et al. Biosynthesized silver and gold nanoparticles are potent antimycotics against opportunistic pathogenic yeasts and dermatophytes. Int J Nanomedicine. 2018;13:695–703.
   PubMed Web of Science ®Google Scholar
• Johnson EA. Phaffia rhodozyma: colorful odyssey. Int Microbiol. 2003;6(3):169–174.
   PubMed Web of Science ®Google Scholar
• Fatemeh N, Sassan R, Ahmad Reza S. Antifungal effects of silver nanoparticle alone and with combination of antifungal drug on dermatophyte pathogen Trichophyton Rubrum. 2011 International Conference on Bioscience, Biochemistry and Bioinformatics IPCBEE; 2011; Singapore: IACSIT Press.
   Google Scholar
• Kumar R, Shukla SK, Pandey A, et al. Copper oxide nanoparticles: an antidermatophytic agent for Trichophyton spp. Nanotechnol Rev. 2015;4(5):401–409.
   Web of Science ®Google Scholar
• Firthouse PM, Halith SM, Wahab S, et al. Formulation and evaluation of miconazole niosomes. Int J Pharmtech Res. 2011;3(2):1019–1022.
   Google Scholar
• Ataei S, Moazeni E, Gilani K, et al. In-vitro evalauation of itraconazole loaded vesicles prepared from non ionic surfactant. J Pharm Sci. 2011;1:50–52.
   Google Scholar
• Brillowska-Dabrowska AH. Pcr diagnostics of dermatophytes and other pathogenic fungi. Denmark: Statens Serum Institut; 2006.
   Google Scholar
• Pier AC. Broad spectrum dermatophyte vaccine. Patent US, Editor. Unites States. 1994.
   Google Scholar
• Gray NM, Woosley RL. Methods ad compositions of (+) ketoconazole for treating fungal yeast and dermatophyte infections. Washington, USA: Sepracor, Inc. Georgetown University; 1999.
   Google Scholar
• Gray NM, Woosley RL, Methods ad compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections. Denmark: Statens Serum Institut; 2000.
   Google Scholar
• Jules Remenar MM, Peterson ML, Morissette SL, et al., Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods. Publication USPA, Editor. Lexington (MA): Transform Pharmaceuticals, Inc.; 2004.
   Google Scholar
• Lynne B, Blank RLG, White WC. Method of treating Tinea pedis and related dermatophytic infections. Midland (MI): Dow Corning Corporation; 1989.
   Google Scholar
• Baker JR, Flack MR, Ciotti SM, et al. Methods of treating fungal, yeast and mold infections. USA: Nanobio Corporation; 2009.
   Google Scholar
• Erik Fred Godefroi CAMVE. Composition and method for combating fungus with imidazole carboxylates. NV: Janssen Pharmaceutica; 1969.
   Google Scholar
• Maibach HI, Luo EC, Hsu T-M. Topical administration of basic antifungal compositions to treat fungal infections of the nails. USA: United state patent; 2005.
   Google Scholar